The Vilas Fund recently published its Q1 2019 Investor Letter (download here), in which it shares its quarterly performance, reporting 34.3% gain in the period. The fund also posted short comments on several holdings, among which were CVS Health Corporation (NYSE:CVS) and Walgreens Boots Alliance, Inc. (NASDAQ:WBA). For these two companies, The Vilas Fund said the following:
“CVS and Walgreens (CVS and WBA)
CVS and Walgreens have had a tough year. The industry has experienced slowing branded drug price inflation, lower generic inflation, and lower reimbursements than expected. We believe all these pressures are temporary. However, it is clear that Amazon has set its sights on the industry, which has dramatically depressed the multiples CVS and Walgreens are trading at. Roughly speaking, both are trading at 8.5-9 times current year earnings estimates, compared to 16-18 times, on average, in the past. Their dividend yields are 3.7% for CVS and 3.2% for Walgreens, both significantly higher than the 2.9% yield on the 30-year US Treasury. Walgreen’s has raised its dividend 45 years in a row, and we expect this trend to continue. When the temporary headwinds subside and partially reverse, we expect the earnings of both to return to the high single digit earnings per share growth range. Additionally, we don’t expect Amazon to be very successful with its strategy given the fact that most people need immediate access to medicine, the incumbents will mail your prescription for free already, and that copays are fixed regardless of where your prescription is filled. Having the option of quickly driving to grab your prescription at roughly 10,000 locations each, often open 24/7, is a valuable service and network effect that we don’t believe will go away. These shares should produce an 18% return without multiple expansion, driven by dividends, retained earnings to be used for expansion, debt repayment or share repurchases, and profit growth from rising prescription volumes. Adding in a 50-70% valuation expansion, and future returns should rise to the mid-20% range over the next 5 years.”
Looker_Studio/Shutterstock.com
CVS Health Corporation is a Woonsocket-based Pharmacy Benefit Manager, and Walgreens Boots Alliance, Inc. is a Deerfield -based holding company, which owns and runs Walgreens, Boots, and other pharmaceutical manufacturers and pharmacy-related businesses. Year-to-date, CVS’ stock lost 15.88% closing on May 10th at $55.16, while WBA’s stock lost 21.49%, and had a closing price on May 10th of $53.42.
Alright, listen up, because the AI game is changing, and you don’t want to get left behind.
Yeah, the chip guys, like Nvidia, they had their moment. The first AI wave? They rode it high.
But guess what? That ride’s over. Nvidia’s been flatlining since June 2024.
Remember the internet boom? Everyone thought Cisco and Intel were the kings, right? Wrong. The real money was made by the companies that actually used the internet to build something new: e-commerce, search engines, social media.
And it’s the same deal with AI. The chipmakers? They’re yesterday’s news. The real winners? They’re the robotics companies, the ones building the robots we only dreamed about before.
We’re talking AI 2.0. The first wave was about the chips, this one’s about the robots. Robots that can do your chores, robots that can work in factories, robots that will change everything. Labor shortages? Gone. Industries revolutionized? You bet.
This isn’t some far-off fantasy, it’s happening right now. And there’s one company, a robotics company, that’s leading the charge. They’ve got the cutting-edge tech, they’re ahead of the curve, and they’re dirt cheap right now. We’re talking potential 100x returns in the next few years. You snooze, you lose.
Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.
We want to make sure none of our valued readers miss out on this groundbreaking opportunity!
That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.
For a ridiculously low price of just $29.99, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!
Here’s why this is a deal you can’t afford to pass up:
• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
• Bonus Reports: Premium access to members-only fund manager video interviews
• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.
Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.
Here’s what to do next:
1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.99.
2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.
Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!
No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!
I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.
We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…
Should I put my money in Artificial Intelligence?
Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.
Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…
But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.
That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…
And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.
He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.